Heart and kidneys – a fatal relationship

Česká verzia

Authors: P. Solík; E. Goncalvesová
Authors place of work: Oddelenie zlyhávania a transplantácie srdca Kardiologickej kliniky Národného ústavu srdcových a cievnych chorôb, a. s., Bratislava, primárka doc. MU Dr. Eva Gonçalvesová, CSc.
Published in the journal: Vnitř Lék 2010; 56(9): 988-994
Category: 60th Birthday - Andrej Dukat MD, Csc., FESC

Summary

Cardiac and renal dysfunction of different degree is common combination in patients in clinical practice. This combination of cardiovascular and renal injury has been defined as a cardiorenal syndrome. The aim of this paper is to offer a comprendious information about actual insights into pathophysiology, terminology, classification and management of cardiorenal syndrome from cardiologist’s point of view.

Key words:
cardiorenal syndrome – acute heart failure – acute kidney injury – chronic heart failure – chronic renal insufficiency

Zdroje

1. Liang KV, Williams AW, Greene EL et al. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 2008; 36 (Suppl 1): S75– S88.

2. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957– 962.

3. Berl T, Henrich W. Kidney‑ heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8– 18.

4. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation 2004; 110: 1514– 1517.

5. Okonko DO, Anker SD. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 2004; 10 (Suppl 1): S5– S9.

6. Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52: 1527– 1539.

7. Bongartz LG, Cramer MJ, Doevendans PA et al. The severe cardiorenal syndrome: “Guyton revisited”. Eur Heart J 2005; 26: 11– 17.

8. Ronco C, McCullough P, Anker SD et al. Cardio‑ renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31: 703– 711.

9. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61– 67.

10. Gottlieb SS, Abraham W, Butler J et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8: 136– 141.

11. Latchamsetty R, Fang J, Kline‑ Rogers E et al. Prognostic value of transient and sustained increase in in‑hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol 2007; 99: 939– 942.

12. Newsome BB, Warnock DG, McClellan WM et al. Long‑term risk of mortality and end‑stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch Intern Med 2008; 168: 609– 616.

13. Logeart D, Tabet JY, Hittinger L et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008; 127: 228– 232.

14. Mullens W, Abrahams Z, Francis GS et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589– 596.

15. Heywood JT, Fonarow GC, Costanzo MR et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13: 422– 430.

16. Dimopoulos K, Diller GP, Koltsida E et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 2008; 117: 2320– 2328.

17. Tonelli M, Wiebe N, Culleton B et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034– 2047.

18. Kubánek M, Burgelová M, Vychodilová T et al. Srdeční selhání u nemocných v dialyzačním programu. Přehled problematiky a návrh algoritmu léčby. Cor Vasa 2010; 52: 229– 233.

19. Bagshaw SM, Lapinsky S, Dial S et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009; 35: 871– 881.

20. Hoste EA, Lameire NH, Vanholder RC et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003; 14: 1022– 1030.

21. Oppert M, Engel C, Brunkhorst FM et al. Acute renal failure in patients with severe sepsis and septic shock – a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008; 23: 904– 909.

22. Charpentier J, Luyt CE, Fulla Y et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32: 660– 665.

23. ver Elst KM, Spapen HD, Nguyen DN et al. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000; 46: 650– 657.

24. Gonçalvesová E. Prínos natriuretických peptidov pre diagnózu, prognózu, manažment a liečbu srdcového zlyhávania. Interní Med 2006; 10: 428– 431.

25. Lesný P. Význam BNP a NT‑ proBNP pri predikcii kardiovaskulárneho rizika. Kardiol Prax 2007; 5: 185– 188.

26. Austin WJ, Bhalla V, Hernandez‑ Arce Iet al. Correlation and prognostic utility of B‑type natriuretic peptide and its amino‑terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126: 506– 512.

27. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003; 4 (Suppl 4): S13– S19.

28. Munagala VK, Burnett JC jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004; 29: 707– 769.

29. Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase‑associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534– 2543.

30. Mishra J, Mori K, Ma Q et al. Neutrophil gelatinase‑associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004; 24: 307– 315.

31. Herget‑ Rosenthal S, Marggraf G, Hüsing J et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115– 1122.

32. Vaidya VS, Ramirez V, Ichimura T et al. Urinary kidney injury molecule‑ 1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290: F517– F529.

33. Liangos O, Perianayagam MC, Vaidya VS et al. Urinary N‑ acetyl‑beta‑(D)‑ glucosaminidase activity and kidney injury molecule‑ 1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007; 18: 904– 912.

34. Uslu S, Efe B, Alataş O et al. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J Nephrol 2005; 18: 559– 567.

35. Harmankaya O, Oztürk Y, Bastürk Tet al. Urinary excretion of N‑ acetyl‑beta‑-D‑ glucosaminidase in newly diagnosed essential hypertensive patients and its changes with effective antihypertensive therapy. Int Urol Nephrol 2001; 32: 583– 584.

36. Fabián J, Gonçalvesová E, Štefanková I.Zlyhávanie a transplantácia srdca. Bratislava: Herba 2007.

37. Damman K, van Deursen VM, Navis G et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53: 582– 588.

38. Dickstein K, Cohen‑ Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388– 2442.

39. National Kidney Foundation. K/ DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1– S266.

40. Gonçalvesová E. Epidémia srdcového zlyhávania – dôsledky, riešenia, východiská. Bratislava: 2008.

41. Owan TE, Chen HH, Frantz RP et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail 2008; 14: 267– 275.

42. Lesný P, Gonçalvesová E, Luknár M et al. Levosimendan pri liečbe srdcového zlyhávania. Cardiol 2005; 14: 301– 306.

43. Lesný P, Oriešek R, Líška B et al. Prediktory krátkodobej mortality a charakteristika pacientov liečených levosimendanom v terciárnom centre a v krajskej nemocnici. Cardiol 2009; 18: 294– 300.

44. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319– 1331.

45. Marenzi G, Lauri G, Grazi M et al. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 2001; 38: 963– 968.

46. Gonçalvesová E, Hulman M, Olejárová I et al. Iniciálne skúsenosti s implantabilnými mechanickými podporami pravej komory v programe transplantácie srdca v Národnom ústave srdcových a cievnych chorôb. Cardiol 2008; 17: 101– 108.

47. Solík P, Murín J. Anaemia in heart failure. Bratisl Lek Listy 2004; 105: 419– 423.

48. Solík P, Murín J. Anémia a chronické srdcové zlyhávanie. Interná med 2007; 7: 309– 315.

49. McCullough PA. Acute kidney injury with iodinated contrast. Crit Care Med 2008; 36 (Suppl 4): S204– S211.

50. Jasuja D, Mor MK, Hartwig KC et al. Provider knowledge of contrast‑induced acute kidney injury. Am J Med Sci 2009; 338: 280– 286.

51. Palevsky PM. Defining contrast‑induced nephropathy. Clin J Am Soc Nephrol 2009; 4: 1151– 1153.

52. Mentzer RM jr, Oz MC, Sladen RN et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol 2007; 49: 716– 726.

53. Silverberg DS, Wexler D, Iaina A et al. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin Exp Nephrol 2009; 13: 101– 106.